mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Company profile
Ticker
MRTX
Exchange
Website
CEO
Charles Baum
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
MethylGene Inc. • Mirati Therapeutics B.V. • Mirati Therapeutics (Suisse) GmbH ...
IRS number
462693615
MRTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Feb 24
EFFECT
Notice of effectiveness
25 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
Transcripts
MRTX
Earnings call transcript
2023 Q2
8 Aug 23
MRTX
Earnings call transcript
2023 Q1
9 May 23
MRTX
Earnings call transcript
2022 Q4
28 Feb 23
MRTX
Earnings call transcript
2022 Q3
8 Nov 22
MRTX
Earnings call transcript
2022 Q2
4 Aug 22
MRTX
Earnings call transcript
2022 Q1
5 May 22
MRTX
Earnings call transcript
2021 Q4
1 Mar 22
MRTX
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
MORGAN STANLEY
9 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
4
JOSEPH LEWIS
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 259.34 mm | 259.34 mm | 259.34 mm | 259.34 mm | 259.34 mm | 259.34 mm |
Cash burn (monthly) | (no burn) | 3.34 mm | 57.35 mm | 63.74 mm | 47.90 mm | 49.51 mm |
Cash used (since last report) | n/a | 22.23 mm | 381.25 mm | 423.71 mm | 318.45 mm | 329.11 mm |
Cash remaining | n/a | 237.11 mm | -121.91 mm | -164.37 mm | -59.11 mm | -69.77 mm |
Runway (months of cash) | n/a | 70.9 | -2.1 | -2.6 | -1.2 | -1.4 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 213 |
Opened positions | 45 |
Closed positions | 38 |
Increased positions | 93 |
Reduced positions | 50 |
13F shares | Current |
---|---|
Total value | 3.48 tn |
Total shares | 80.53 mm |
Total puts | 407.50 k |
Total calls | 1.31 mm |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 6.77 mm | $294.84 bn |
Avoro Capital Advisors | 6.67 mm | $290.40 bn |
EcoR1 Capital | 5.75 mm | $250.40 bn |
Vanguard | 5.70 mm | $248.28 bn |
BLK Blackrock | 3.54 mm | $154.39 bn |
Wellington Management | 3.32 mm | $144.62 bn |
Boxer Capital | 3.20 mm | $139.45 bn |
Aviva | 3.14 mm | $136.60 bn |
STT State Street | 2.75 mm | $119.61 bn |
MS Morgan Stanley | 2.46 mm | $107.25 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 24 | Christensen Jamie | Common Stock | Sale back to company | Dispose D | No | No | 0 | 17,021 | 0.00 | 0 |
23 Jan 24 | Christensen Jamie | Common Stock | Sale back to company | Dispose D | No | No | 0 | 81,480 | 0.00 | 17,021 |
23 Jan 24 | Christensen Jamie | Common Stock | Sale back to company | Dispose D | No | No | 0 | 56,495 | 0.00 | 98,501 |
23 Jan 24 | Christensen Jamie | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 64.14 | 58,750 | 3.77 mm | 0 |
23 Jan 24 | Christensen Jamie | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 64.14 | 1,250 | 80.18 k | 0 |
23 Jan 24 | Christensen Jamie | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 45.66 | 43,329 | 1.98 mm | 0 |
23 Jan 24 | Christensen Jamie | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 45.66 | 2,127 | 97.12 k | 0 |
23 Jan 24 | Christensen Jamie | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 39.76 | 28,617 | 1.14 mm | 0 |
23 Jan 24 | Christensen Jamie | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 39.76 | 1,383 | 54.99 k | 0 |
23 Jan 24 | Christensen Jamie | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 27 | 74,838 | 2.02 mm | 0 |